Table 1 Baseline characteristics of 500 colonoscopic findings in 333 patients with ulcerative colitis
From: Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis
Patient characteristics | Number (%) |
|---|---|
Total N | 333 patients |
Sex | |
Male, n (%) | 218 (65.5) |
Female, n (%) | 115 (35.5) |
Mean Age (years, range) | 44.13 ± 17.78 (17–80) |
Total N | 500 colonoscopic findings |
Disease duration (month, range) | 37.37 ± 48.88 (1–288) |
Disease extent at last examination | |
Proctitis (n, %) | 206 (41.2) |
Left-sided colitis (n, %) | 148 (29.6) |
Extensive colitis (n, %) | 146 (29.2) |
Treatment modality | |
Topical 5-ASA | 234 (46.8) |
Oral 5-ASA | 440 (88.0) |
Glucocorticoid | 125 (25.0) |
Immunomodulator | 141 (28.2) |
Biologics | 70 (14.0) |
Indication for colonoscopy | |
Response after initial diagnosis | 103 (20.6) |
Flare-up | 188 (37.6) |
Surveillance (No symptom) | 209 (41.8) |
Total Mayo score | 3.57 ± 3.18(0–12) |
Hospitalization | |
Outpatient | 453 (87.0) |
Inpatient | 65 (13.0) |
Laboratory findings | |
CRP (mg/dL) | 1.46 ± 5.21 (0–55) |
Fecal calprotectin (μg/g) | 621.65 ± 777.18 (0–3409) |